Evidence map›Paper›PMID 36325271›Full record

ArticleHemaSphere2022

Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment.

Tom A Mulder, Maria L Andersson, Lucía Peña-Pérez, Kia Heimersson, Ioanna Xagoraris, Björn E Wahlin, Robert Månsson, Lotta Hansson, Georgios Rassidakis, Marzia Palma

Abstract read
In one paragraph

Article in HemaSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Prognostic value of a novel myeloid-to-lymphoid ratio biomarker in advanced gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tom A MulderDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Maria L AnderssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Lucía Peña-PérezDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Kia HeimerssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Ioanna XagorarisDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Björn E WahlinDepartment of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Robert MånssonDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Lotta HanssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Georgios RassidakisDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Marzia PalmaDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In classical Hodgkin lymphoma (cHL), the malignant cells represent only a small fraction of the tumor. Yet, they orchestrate a lymphocyte-dominated tumor microenvironment (TME) that supports their survival and growth. The systemic effects of this local immunomodulation are not fully elucidated. Here, we aimed at characterizing circulating lymphocytes and plasma proteins in relation to clinical parameters and treatment effect. Peripheral blood (PB) samples were obtained from 48 consecutive patients at diagnosis and at 2 time points after successful primary treatment. Single-cell suspensions were prepared from lymph node (LN) biopsies obtained for routine diagnostic purposes. Twenty healthy individuals were included as controls. Cells from PB and LN were analyzed by flow cytometry, and plasma proteins by Proximity Extension Assay. We found that the frequencies of T and B cells positively correlated between the LN and the PB compartments. Compared to controls, cHL patients had higher frequencies of proliferating T cells as well as higher expression of programmed death (PD)-1 and cytotoxic T lymphocyte antigen (CTLA)-4 in circulating T cells, and lower naive T-cell frequencies. Advanced-stage patients had fewer NK cells with a functionally impaired phenotype. Differences in the immune profile were observed in patients with a high tumor burden and with high inflammation, respectively. Most of these deviations disappeared after standard first-line treatment. Patients who received radiotherapy involving the mediastinum had low T-cell counts for a prolonged period. Our findings suggest that the immunomodulation of lymphocytes in the TME of cHL might affect immune biomarkers in the PB.

Identifiers

PMID36325271
PMCPMC9619233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.